company background image
ALPN

Alpine Immune Sciences NasdaqGM:ALPN Stock Report

Last Price

US$7.63

Market Cap

US$350.3m

7D

-7.2%

1Y

-10.2%

Updated

30 Jan, 2023

Data

Company Financials +

Alpine Immune Sciences, Inc.

NasdaqGM:ALPN Stock Report

Mkt Cap: US$350.3m

ALPN Stock Overview

Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases.

ALPN fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

New

Notes are coming soon

Alpine Immune Sciences, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Alpine Immune Sciences
Historical stock prices
Current Share PriceUS$7.63
52 Week HighUS$10.30
52 Week LowUS$4.82
Beta1.31
1 Month Change3.81%
3 Month Change25.49%
1 Year Change-10.24%
3 Year Change159.52%
5 Year Change-26.42%
Change since IPO-20.10%

Recent News & Updates

Is Alpine Immune Sciences (NASDAQ:ALPN) Weighed On By Its Debt Load?

Dec 12
Is Alpine Immune Sciences (NASDAQ:ALPN) Weighed On By Its Debt Load?

Recent updates

Is Alpine Immune Sciences (NASDAQ:ALPN) Weighed On By Its Debt Load?

Dec 12
Is Alpine Immune Sciences (NASDAQ:ALPN) Weighed On By Its Debt Load?

Despite Lacking Profits Alpine Immune Sciences (NASDAQ:ALPN) Seems To Be On Top Of Its Debt

Aug 09
Despite Lacking Profits Alpine Immune Sciences (NASDAQ:ALPN) Seems To Be On Top Of Its Debt

Is Alpine Immune Sciences (NASDAQ:ALPN) A Risky Investment?

Apr 12
Is Alpine Immune Sciences (NASDAQ:ALPN) A Risky Investment?

Rock star Growth Puts Alpine Immune Sciences (NASDAQ:ALPN) In A Position To Use Debt

Sep 18
Rock star Growth Puts Alpine Immune Sciences (NASDAQ:ALPN) In A Position To Use Debt

Industry Analysts Just Upgraded Their Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Revenue Forecasts By 42%

Aug 18
Industry Analysts Just Upgraded Their Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Revenue Forecasts By 42%

We Think The Compensation For Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) CEO Looks About Right

Jun 03
We Think The Compensation For Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) CEO Looks About Right

Alpine Immune Sciences (NASDAQ:ALPN) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Mar 29
Alpine Immune Sciences (NASDAQ:ALPN) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

How Many Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Shares Did Insiders Buy, In The Last Year?

Mar 03
How Many Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Shares Did Insiders Buy, In The Last Year?

The Alpine Immune Sciences (NASDAQ:ALPN) Share Price Is Up 316% And Shareholders Are Delighted

Feb 05
The Alpine Immune Sciences (NASDAQ:ALPN) Share Price Is Up 316% And Shareholders Are Delighted

What Kind Of Shareholders Own Alpine Immune Sciences, Inc. (NASDAQ:ALPN)?

Jan 10
What Kind Of Shareholders Own Alpine Immune Sciences, Inc. (NASDAQ:ALPN)?

Does Alpine Immune Sciences (NASDAQ:ALPN) Have A Healthy Balance Sheet?

Dec 15
Does Alpine Immune Sciences (NASDAQ:ALPN) Have A Healthy Balance Sheet?

Robert Conway Is The Independent Director of Alpine Immune Sciences, Inc. (NASDAQ:ALPN) And They Just Picked Up 67% More Shares

Nov 24
Robert Conway Is The Independent Director of Alpine Immune Sciences, Inc. (NASDAQ:ALPN) And They Just Picked Up 67% More Shares

Shareholder Returns

ALPNUS BiotechsUS Market
7D-7.2%0.8%2.8%
1Y-10.2%7.1%-9.2%

Return vs Industry: ALPN underperformed the US Biotechs industry which returned 7.1% over the past year.

Return vs Market: ALPN matched the US Market which returned -9.2% over the past year.

Price Volatility

Is ALPN's price volatile compared to industry and market?
ALPN volatility
ALPN Average Weekly Movement9.7%
Biotechs Industry Average Movement12.2%
Market Average Movement6.9%
10% most volatile stocks in US Market17.3%
10% least volatile stocks in US Market2.8%

Stable Share Price: ALPN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: ALPN's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200785Mitch Goldhttps://www.alpineimmunesciences.com

Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products.

Alpine Immune Sciences, Inc. Fundamentals Summary

How do Alpine Immune Sciences's earnings and revenue compare to its market cap?
ALPN fundamental statistics
Market CapUS$350.33m
Earnings (TTM)-US$54.06m
Revenue (TTM)US$31.82m

11.0x

P/S Ratio

-6.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ALPN income statement (TTM)
RevenueUS$31.82m
Cost of RevenueUS$66.85m
Gross Profit-US$35.03m
Other ExpensesUS$19.03m
Earnings-US$54.06m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.18
Gross Margin-110.10%
Net Profit Margin-169.92%
Debt/Equity Ratio2.5%

How did ALPN perform over the long term?

See historical performance and comparison